CYDY
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.00 | $0 | -$6M |
| 2025 Q2 | -0.02 | $0 | -$4M |
| 2025 Q1 | -0.00 | $0 | -$2M |
| 2025 Q4 | -0.01 | -$6M | -$6M |
| 2025 Q3 | -0.00 | $0 | -$5M |
| 2024 Q2 | -0.00 | $0 | -$4M |
| 2024 Q1 | 0.02 | $0 | $5M |
| 2024 Q4 | -0.02 | $50,000 | -$2M |